Blog
RSS FeedPosted by Michael Wonder on 11 Mar 2016
Call for patient input on a submission from Hospira for a subsequent entry biologic
11 March 2016 - CADTH has received notice of a pending submission from Hospira for Inflectra (infliximab) for the treatment of ...
Posted by Michael Wonder on 09 Mar 2016
Call for patient input on a submission from Merck for a subsequent entry biologic
9 March 2016 - CADTH has received notice of a pending submission from Merck for etanercept for use by certain patients ...
Posted by Michael Wonder on 01 Mar 2016
CADTH to provide drug plans with copies of CDR submission or resubmission materials
25 February 2016 - CADTH has begun providing authorized recipients from the CDR-participating drug plans with copies of all category 1 ...
Posted by Michael Wonder on 26 Feb 2016
Update on procedures for the CADTH Common Drug Review and pan-Canadian Oncology Drug Review: mandatory disclosure of a submitted drug price
25 February 2016 - In late September 2015, CADTH invited stakeholder comments and feedback on proposed revisions to the CADTH Common ...
Posted by Michael Wonder on 23 Feb 2016
Call for feedback: new drugs for type 2 diabetes: a therapeutic review update
22 February 2016 - A proposed CADTH project scope on new drugs for type 2 diabetes mellitus: a therapeutic review update ...
Posted by Michael Wonder on 06 Feb 2016
CADTH calls for patient input on submissions for 2 new medicines for use by patients with HIV infection
5 February 2016 - CADTH has received notice of pending submissions from Theratechnologies for Egrifta (tesamorelin acetate) for lipodystrophy in HIV-infected ...
Posted by Michael Wonder on 01 Feb 2016
CADTH calls for patient input on a new submission from Genzyme for Cerdelga
1 February 2016 - CADTH has received notice of a pending submission from Genzyme for Cerdelga (eliglustat tartrate) for the treatment ...
Posted by Michael Wonder on 30 Jan 2016
CADTH calls for patient input on a new submission from Celgene for Otezla
29 January 2016 - CADTH has received notice of a pending resubmission from Celgene for Otezla (apremilast) for use by patients ...
Posted by Michael Wonder on 21 Jan 2016
CADTH calls for patient input on two submissions from Novartis for Cosentyx
21 January 2016 - CADTH has received notice of pending submissions from Novartis for Cosentyx (secukinumab) for use by patients with ...
Posted by Michael Wonder on 16 Jan 2016
CADTH calls for patient input on a new submission from AstraZeneca for Brilinta
15 January 2016 - CADTH has received notice of a pending submission from AstraZeneca for ticagrelor (Brilinta) for the prevention of ...
Posted by Michael Wonder on 07 Jan 2016
CADTH calls for patient input on submissions requesting advice on recent recommendations for new hepatitis C medicines
6 January 2016 - CADTH has received submissions requesting advice for Sovaldi, Harvoni, Holkira Pak & Daklinza. ...
Posted by Michael Wonder on 05 Jan 2016
Final CADTH reports on drugs for chronic hepatitis C infection
5 January 2016 - CADTH updated its previous therapeutic review examining the clinical and economic impact of new and existing drugs ...
Posted by Michael Wonder on 07 Dec 2015
CADTH calls for patient input on a new submission from Sanofi for Praluent
7 December 2015 - CADTH has received notice of a pending submission from Sanofi for Praluent (alirocumab) for use by patients ...
Posted by Michael Wonder on 24 Nov 2015
CADTH calls for patient input on a new submission from Novartis for Ilaris
24 November 2015 - CADTH has received notice of a pending submission from Novartis for canakinumab (Ilaris) for use by patients ...
Posted by Michael Wonder on 20 Nov 2015
CADTH calls for patient input on a new submission from GSK for mepolizumab
20 November 2015 - CADTH has received notice of a pending submission from GSK for mepolizumab for use by patients with ...